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To accomplish their viral life cycle, lentiviruses such as HIV highjack host proteins, the so-called cellular
co-factors of replication. Lens Epithelium-derived Growth factor (LEDGF/p75), a transcriptional
co-activator, is a co-factor of HIV-integrase (IN) and is required for the tethering and correct integration
of the viral genome into the host chromatin. Due to its important role in HIV-replication the LEDGF/
p75–IN interaction is an attractive antiviral novel target for the treatment of HIV/AIDS. Intensive drug
discovery efforts over the past years have validated the LEDGF/p75–IN interaction as a drugable target
for antiviral therapy and have resulted in the design and synthesis of LEDGINs, small molecule
inhibitors binding to the dimer interface of HIV-integrase and inhibiting viral replication with a dual
mechanism of action: potent inhibition of the LEDGF/p75–IN protein–protein interaction and allosteric
inhibition of the catalytic function. Furthermore they inhibit both early and late steps of the replication
cycle which increases their potential for further clinical development. In this review we will highlight
the research validating the LEDGF/p75–IN interaction as a target for anti-HIV drug discovery and the
recent advances in the design and development of LEDGINs.
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Integration of the viral DNA into the host cell genome is a
critical step during HIV replication. A stably inserted provirus
enables productive infection and permanently archives the
genetic information of HIV in the host. Due to its limited genome,
HIV needs to rely on cellular co-factors for provirus establishment
and efﬁcient replication in the host cell (Van Maele et al., 2006).
LEDGF/p75, a transcriptional co-activator (Ganapathy et al.,
2003; Ge et al., 1998; Singh et al., 2000a), was initially identiﬁedll rights reserved.
. Christ).as an integrase co-factor by co-immunoprecipitation from cells
overexpressing HIV-IN (Cherepanov et al., 2003). LEDGF/p75 is a
member of the hepatoma-derived growth factor family (HDGF),
composed of chromatin-associated proteins sharing certain struc-
tural features. The crucial role of LEDGF/p75 in HIV replication
was evidenced via mutagenesis, RNAi-mediated depletion, trans-
dominant overexpression of the integrase binding domain (IBD)
of LEDGF/p75 and knock out studies (Busschots et al., 2007;
Cherepanov et al., 2003; Ciufﬁ et al., 2005; De Rijck et al., 2006;
Emiliani et al., 2005; Hombrouck et al., 2007a; Llano et al., 2006a;
Schrijvers et al., 2012; Shun et al., 2007a, 2007b; Vandekerckhove
et al., 2006). LEDGF is encoded by the PSIP1 (PC4- and SFRS-
interacting protein 1) gene on the human chromosome 9 and is
expressed as two splice variants the LEDGF/p52 and LEDGF/p75
Fig. 1. Domain organization of LEDGF and HIV-integrase and crystal structure of their interaction. (A) LEDGF/p75 binding to DNA is mediated by the NLS and the
nearby located AT-hook DNA binding motives whereas the N-terminal PWWP motive and charged regions (CR1-3) are critical for chromatin recognition (Hendrix et al.,
2011; Llano et al., 2006b; McNeely et al., 2011; Turlure et al., 2006). The C-terminal IBD is essential for integrase binding (Cherepanov et al., 2004, 2005b) and for the
interaction with cellular proteins that bind LEDGF/p75 (Bartholomeeusen et al., 2007, 2009; Maertens et al., 2006; Yokoyama and Cleary, 2008). (B) The 325 N-terminal
residues of LEDGF/p52 are identical with LEDGF/p75 and therefore both splice variants share their chromatin/DNA binding preferences. The p52 isoform though harbors a
unique eight amino acid sequence at its C-terminus (Singh et al., 2000a). (C) HIV-IN consists of three distinct domains: the N-terminal domain (NTD) with the conserved
HHCC zinc ﬁnger motives, the catalytic core domain (CCD) housing the transposase speciﬁc catalytic triade (D64, D116, E152) and the C-terminal domain (CTD) involved in
multimerization and DNA-binding. (D) The co-crystal structure of LEDGF/p75–IBD (magenta) and the CCD dimer of integrase (green and blue) reveals that the integrase
CCD dimer-interface forms a cavity in which the connecting loops of the IBD 5 a-helixes bundle protrudes. Highlighting the catalytic triad in yellow visualizes that the
LEDGF/p75 interaction pocket in IN is distinct from the catalytic site (PDB accession code 2B4J; Cherepanov et al., 2005a).
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region (aa 1–325) and therefore the nuclear localization and
chromatin-binding elements deﬁned by the PWWP (Pro–Trp–
Trp–Pro) domain (Dietz et al., 2002; Izumoto et al., 1997; Stec
et al., 2000), the nuclear localization signal (NLS), the A/T hook
like elements (Aravind and Landsman, 1998) and three charged
regions (CR1, CR2 and CR3) (Llano et al., 2006a; Turlure et al.,
2006). The C-terminal region though differs and is much extended
in p75 (Fig. 1A). The larger splice variant p75 therefore exclusively
contains the integrase binding domain (IBD, aa347–429).
Although this domain was originally characterized by its associa-
tion with HIV-IN (Cherepanov et al., 2004) later studies have
shown that different cellular binding partners interact with
LEDGF/p75 through this domain (Bartholomeeusen et al., 2007,
2009; Maertens et al., 2006; Yokoyama and Cleary, 2008). LEDGF/
p52 (Fig. 1B) contains eight unique aa in its C-terminus (Ge et al.,
1998) and fails to interact with HIV-IN (Maertens et al., 2003;
Shun et al., 2007b). Co-localization studies mapped the LEDGF/
p75 interaction site on IN (Fig. 1C) to the catalytic core domain
and to a less extent to the N-terminal domain (Maertens et al.,
2003). Through its classical NLS LEDGF/p75 is predominantly
located in the nucleus where it associates with chromatin through
its PWWP domain. During HIV replication it thereby tethers IN
associated with the viral genome to the host chromatin facilitat-
ing the integration into HIV-preferred sites (Ciufﬁ et al., 2005;
Gijsbers et al., 2011; Maertens et al., 2003; Marshall et al., 2007;
Nishizawa et al., 2001; Shun et al., 2007b; Tsutsui et al., 2011).
Next to its tethering function LEDGF/p75 protects IN from
proteolytic degradation and stimulates the catalytic activity of
IN in vitro as well as in in vivo (Cherepanov et al., 2003; Hendrix
et al., 2011; Llano et al., 2004; Maertens et al., 2003; Turlure et al.,
2006). Evidence from integration sites analysis in human cells
depleted of LEDGF/p75 by RNAi, in embryonic ﬁbroblasts derived
from LEDGF knockout mice or in human B-cell lines with aspeciﬁc LEDGF/p75 knock out corroborated this role of LEDGF/
p75 as tethering and targeting factor of HIV (Ciufﬁ et al., 2005;
Gijsbers et al., 2011; Schrijvers et al., 2012; Shun et al., 2007a).Targeting HIV-IN in anti-HIV therapy
Since the ﬁrst description of the acquired immune deﬁciency
syndrome (AIDS) in 1981, worldwide more than 25 million people
have fallen victim to HIV infections. Despite the enormous efforts
in developing new effective antivirals and the introduction of
highly active antiretroviral therapy (HAART), the incidence of HIV
infections remains a major problem in public health. Although
HIV replication can be chronically suppressed with proper HAART,
no cure is in sight. Therefore the quest for novel antivirals to
complement existing treatment strategies remains one of the
major goals in HIV drug discovery. Classical drugs target the viral
enzymes reverse transcriptase, protease and integrase. Raltegravir
(Isentress, MK-518) interferes with the strand transfer reaction of
viral integrase and has been approved for clinical use (Summa
et al., 2008). Raltegravir is the prototypical integrase strand
transfer inhibitor (INSTI). Inhibition of integration by raltegravir
is accompanied by extremely fast and strong reduction in viral
load (Murray et al., 2007). However, in contrast to prior predic-
tions based on in vitro experimentation, raltegravir resistance
evolves readily in the clinic (Malet et al., 2008) even in the
presence of optimized highly active antiretroviral treatment
(HAART) regiments (Baldanti et al., 2010), boosting the efforts
to develop second generation integrase inhibitors. Since the
development of raltegravir, there has been a strong interest in
developing true second generation IN inhibitors lacking cross-
resistance. Nevertheless in the past years it has been proven
difﬁcult to develop novel antivirals with a beneﬁcial resistance
proﬁle over raltegravir or an improved pharmacokinetics (PK) in
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doses. Elvitegravir (Shimura et al., 2008; Zolopa et al., 2010), a
Phase III INSTI, can be administered once daily if combined with a
pharmacological booster, but is cross-resistant with raltegravir and
therefore is no treatment option for patients failing on INSTIs. S/
GSK1349572 (Dolutegravir) yet another Phase III clinical trial INSTI
displays superior characteristics to raltegravir, but partially shares
the resistance pathways (Garrido et al., 2011; Min et al., 2011). Due
to the limited chemical space available for designing inhibitors of
the catalytic activity of IN inevitable overlap of resistance for
second generation integrase strand transfer inhibitors is likely;
therefore efforts have moved toward novel mechanism of action
such as the design of inhibitors with an allosteric mechanism of
action or inhibitors of interactions with essential cellular co-factors
of integration, such as the LEDGF/p75–IN interaction.Fig. 2. The LEDGF/p75–IN interaction is mediated by several tight interactions
between both protein binding partners. (PDB accession code 2B4J; Cherepanov
et al., 2005a) Cartoon representation of the CCD–IBD complex. IN CCD molecules
are shown in green and blue, whereas the LEDGF/p75 IBD is colored in magenta.
Residues critical for the interaction and identiﬁed through biochemical character-
ization and resistance selection (Busschots et al., 2007; Hombrouck et al., 2007b)
are shown in stick representation and highlighted (L368, I365, D366 and K364
from LEDGF/p75 and A128, H171 and E170 from HIV-IN).Does the LEDGF/p75–IN interaction qualify as a drug target for
anti-HIV therapy?
In 2005 the crystal structure of IBD in complex with a dimer of
the integrase catalytic core domain was reported (Fig. 1D; PDB
code: 2B4J; Cherepanov et al., 2005a), identifying the amino acid
residues of LEDGF/p75 mediating the interaction with IN (Lys364,
Ile365, Asp366, Phe406, Val408). The IBD structure is composed of
a right handed compact bundle of 4 a-helices. The amino acid
residues contacting HIV-IN are located on the interhelical loop
regions of the structure. In integrase two regions of the catalytic
core domain are in direct contact with LEDGF/p75, namely the
region around Trp131 and Trp132 and the region extending from
Ile161 to Glu170 (Busschots et al., 2007; Cherepanov et al., 2005a;
Emiliani et al., 2005). The interface is located in a pocket formed
by the two subunits of the IN-core dimer (a1 and a3 of one
monomer and the six residues from the a4/5 connector in the
other monomer). Residues located in the a4/5 connector and a
hydrophobic pocket formed by the other subunit engage tightly
with the two inter-helical loops of LEDGF/p75–IBD. Speciﬁcally
the side chain of LEDGF/p75 Ile365 contacts the hydrophobic
pocket formed by Leu102, Ala128, ALA129, Trp132 of one IN
subunit and Thr174 and Met178 of the other subunit. Further-
more Ile365 establishes a hydrogen bond with the backbone
carbonyl group of IN Gln168 whereas Asp366 of LEDGF/p75 forms
a hydrogen bond with Glu170 (Cherepanov et al., 2005a). The
importance of aa Ala128, His170, Thr174, Trp131, Trp132, Gln168
and Glu170 have been conﬁrmed by mutagenesis studies. Muta-
tion of these residues on integrase renders the protein defective
or deﬁcient for LEDGF/p75 interaction (Busschots et al., 2007;
Cherepanov et al., 2005a; Emiliani et al., 2005; Hombrouck et al.,
2007a). Vice versa substitution of aa residues Ile365, Asp366,
Phe406 and Val408 decreased or abolished binding of LEDGF/p75
to integrase (Cherepanov et al., 2005b). Therefore the protein–
protein interaction surface of LEDGF/p75 and IN provides a well-
deﬁned pocket, limited in its extension and with multiple hydro-
phobic and hydrogen bond interactions indicating that its disrup-
tion by small molecules is a feasible endeavor.
Depletion of LEDGF/p75 from cells by RNAi or knock-out
techniques signiﬁcantly reduced infectivity of HIV in those cells
(Llano et al., 2006a; Schrijvers et al., 2012; Shun et al., 2007b;
Vandekerckhove et al., 2006). Together with the overexpression of
the IBD of LEDGF/p75 in human cells (De Rijck et al., 2006), these
ﬁndings provided proof-of-concept that the LEDGF/p75-IN inter-
action might be a feasible and druggable target for anti-HIV
therapy. IBD, lacking the chromatin binding domain, could
efﬁciently compete with the endogenous cofactor and inhibited
HIV replication and integration more than 100-fold (De Rijck
et al., 2006). Moreover by serial passaging of HIV in cellsoverexpressing this LEDGF/p75 fragment, a virus strain resistant
to this phenotype was selected (Hombrouck et al., 2007a). Inter-
estingly two mutations in integrase were required to render IN
resistant: A128T and E170G, conﬁrming the mutagenesis data and
the validity of the IBD/IN catalytic core domain structure (Fig. 2;
Busschots et al., 2007; Cherepanov et al., 2005a). Further support
was granted by the reports of Al-Mawsawi et al. (2008) and
Hayouka et al. (2007) demonstrating that short peptides derived
from LEDGF/p75 block the interaction between LEDGF/p75 and
IN. Even though peptides are not the compounds of choice for
targeting intracellular targets and drug development, this work
provided further support for the notion that the LEDGF/p75–IN
interaction is a likely target for anti-HIV drug development. Since
then different groups in academia and industry have embarked on
targeting this virus–host interaction for anti-HIV drug discovery.
Different approaches have been employed to design and identify
small-molecule inhibitors of the LEDGF/p75–IN interaction. These
include high throughput screening (HTS) of diverse chemical
libraries, computational database screening of virtual small
molecule libraries and structure-based design of de novo small
molecules on the basis of pharmacophore models.Peptides inhibiting the LEDGF/p75–IN interaction
Although peptides pose notorious problems when it comes to
stability and bioavailability, the design of small synthetic peptides
interacting with one of the binding partners of a protein–protein
interaction is a valid starting point to facilitate the development
of peptidomimetics or genuine small molecule inhibitors. Due to
the linearity of the interacting aa sequence of the IBD initial work
focused on peptides derived from the LEDGF/p75 sequence
(Al-Mawsawi et al., 2008; Hayouka et al., 2010a; Rhodes et al.,
2011). Hayouka et al. (2007) described the design and synthesis of
three LEDGF/p75 derived peptides (LEDGF/p75 353–378, 361–370
and 402–411). As LEDGF/p75 was reported earlier to preferen-
tially bind to the tetrameric state of IN (Cherepanov et al., 2003)
the authors reasoned that small peptides derived from LEDGF/
p75, interacting with the LEDGF/p75 binding pocket on IN should
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catalytic activity of IN. Indeed they observed that the peptides
shifted the oligomerization state of IN toward the tetrameric form
resulting in inhibition of IN–DNA binding and as a consequence of
both catalytic activities namely the 30 processing and the strand
transfer. In this report though inhibition of the LEDGF/p75–IN
interaction by the described peptides was not presented and the
authors attributed the observed anti-viral effect solely to the
inhibition of the IN catalytic activity. One year later it was
reported that a similar peptide (LEDGF/p75 355–377) was capable
of competing with LEDGF/p75 for the binding to integrase and
therefore inhibiting the cofactor-IN interaction with an IC50 of
25 mM (Al-Mawsawi et al., 2008) in a alphascreen based interac-
tion assay (Christ et al., 2010; Hombrouck et al., 2007b; Hou et al.,
2008). The inhibition of the catalytic activity (both 30 processing
and strand transfer) was less pronounced for this peptide and was
lost when the IN–DNA complex was assembled prior to addition
of the peptide (Al-Mawsawi et al., 2008) which led to the
hypothesis that the peptide might disrupt initial DNA-binding of
integrase and as such exerts its effect on the catalytic activity,
namely the 30 processing reaction. The mechanism of action of
shorter peptides (LEDGF/p75 361–370) was studied in detail by
biophysical, biochemical and cellular assays (Hayouka et al.,
2010b). A peptide as short as LEDGF/p75 365–369 was described
to bind to the catalytic core domain of HIV-IN as demonstrated by
ﬂuorescence anisotrophy, but it was not sufﬁcient to inhibit IN
function. The authors identiﬁed LEDGF/p75 361–370 as the
minimal inhibitory peptide. This LEDGF/p75 derived peptide
was then cyclized in a later study (Hayouka et al., 2010a,
2010b) increasing its IN inhibitory activity. LEDGF/p75 derived
cyclic peptides have also been used by Rhodes et al. (2011) in
order to identify new interactions in the LEDGF/p75–IN interac-
tion interface. In this study a cyclic peptide was formed using the
LEDGF/p75 362–367 sequence fused to three additional amino
acids (H–SLKIDNLDVNS–OH). High resolution crystallography of
in total 13 cyclic peptides constructed from this original sequence
bound to the LEDGF/p75 binding pocket in integrase revealed that
seven out of the eight aa residues present in LEDGF/p75 make
contacts with the binding pocket in integrase covering a surface
area of 420 A˚ and stabilizing the conformation of the peptide by
extensive intramolecular interactions. Not all contacts described
in this study were known before. The previously undescribed
interactions observed in this study, in particular a hydrogen bond
interaction with IN–Glu168, gave valuable input for structure-
based design efforts to develop novel small molecules inhibiting
the LEDGF/p75–IN interaction as the authors have shown in a
follow-up structure based design study reviewed below.
Recently our group has published a novel reciprocal peptide
approach (Desimmie et al., 2012). In contrast to the earlier work
using peptides derived from the LEDGF/p75–IBD primary
sequence binding to the dimer interface of IN, here peptides were
designed to bind to LEDGF/p75 and as a consequence to inhibit
the LEDGF/p75 integrase interaction from the side of the cellular
co-factor. As the LEDGF/p75 binding pocket in integrase is not
linear and therefore cannot guide development of IN-derived
inhibitory peptides, a phage display strategy was employed to
select for peptides with afﬁnity for the integrase interaction side
of IBD. From three different linear and cyclic phage display
libraries multiple peptides were selected with moderate afﬁnity
for LEDGF/p75. Interestingly the sequence motive VM/XGHPL/XW
was repeatedly found. Synthesis of cyclic peptides containing this
sequence motive indeed yielded small cyclic peptide inhibitors of
the LEDGF/p75–IN interaction. As peptides are notoriously difﬁ-
cult to be delivered to cells, stable lentiviral expression of selected
active and mutant peptides was chosen. As expected, expression
of active peptides led to potent inhibition of HIV-replication.Biochemical and biophysical studies as well as antiviral proﬁling
demonstrated that the selected peptides indeed inhibit
HIV-replication through their binding to the cellular co-factor
LEDGF/p75 (Desimmie et al., 2012). It was reassuring to observe
that although the peptides bind to the IBD of LEDGF/p75 no
cellular toxicity was observed. This observation is in accord with
previous reports describing that although IN shares the overall
binding site (IBD) on LEDGF/p75 with different cellular interact-
ing partners such as PogZ and JPO2, the detailed architecture of
the interaction is distinct (Bartholomeeusen et al., 2007, 2009;
Maertens et al., 2006). Due to the interaction with a cellular co-
factor instead of a viral protein resistance selection failed. Taken
together the study by Desimmie et al. provides proof-of concept
that intracellular co-factors such as LEDGF/p75 are drug targets
for antiviral therapy which might come at the beneﬁt of a higher
barrier toward resistance selection. As the described consensus
sequence (Desimmie et al., 2012) is limited in size the cyclic
peptides might serve as templates for genuine peptidomimetic
drugs.LEDGINs, small molecules binding to the LEDGF/p75 binding
pocket of integrase inhibit diverse integrase functions
The ﬂatness of protein–protein interfaces often hampers the
identiﬁcation of small molecule protein–protein interaction
inhibitors (SMPPIIs). LEDGF/p75 though binds to a deﬁned pocket
in the dimer interface of the HIV-IN catalytic core domain. Due to
the tight interface of the LEDGF/p75–IN interaction (Cherepanov
et al., 2005a) the design and/or selection of small molecules
binding to this pocket is a feasible endeavor. Although a HTS
approach has been described (Hou et al., 2008), most efforts so far
have emanated from in silico virtual screening of compound
libraries and structure-based de novo design (Christ et al., 2012,
2010; De Luca et al., 2009, 2010; Du et al., 2008; Fan et al., 2011;
Peat et al., 2012). The knowledge-driven, computer aided
approach usually yields a limited subset of small molecules, with
chemical features deﬁned by the applied screening algorithm.
This limited selection of molecules is then evaluated for their
biological activity.
Albeit different classes of LEDGINs with high variability in
their biological activity have been described so far, they all share
certain characteristics. In contrast to INSTIs, which bind to the
catalytic site after integrase has assembled on its DNA substrate
(long terminal repeat sequences, LTRs; Espeseth et al., 2000; Hare
et al., 2010), LEDGINs bind to the dimer interface of integrase
irrespective of the assembly with LTRs, as demonstrated by
crystallography (Christ et al., 2010; Peat et al., 2012) or modeling
(De Luca et al., 2009, 2008; Du et al., 2008; Fan et al., 2011;
Hu et al., 2012). In addition, if the tested molecules reach a critical
level in potency, they exert a dual mechanism of action blocking
the LEDGF/p75–IN interaction and simultaneously modulating
the multimerization state of IN resulting in the allosteric inhibi-
tion of the integrase catalytic activity (Christ et al., 2012, 2010;
Kessl et al., 2012; Tsiang et al., 2012).
Even before the identiﬁcation and validation of LEDGF/p75 as a
co-factor of HIV integration tetraphenyl arsonium was identiﬁed by
crystallography to bind to the dimer interface of the catalytic core
domain (Molteni et al., 2001). Although this molecule does inhibit
neither integrase activity nor the interaction with LEDGF/p75, it
provided valuable information for later structure-based design
efforts (Christ et al., 2010).
Du et al. (2008) described a commercially available benzoic
acid derivative, D77 (Fig. 3A). Molecular docking studies in
combination with site-directed mutagenesis and surface plasmon
resonance (SPR) identiﬁed this molecule as a potential binder to
Fig. 3. Different classes of LEDGINS, inhibiting the LEDGF/p75–IN interaction. (A) Selected chemical structures of LEDGINs (D77, Du et al., 2008; BI-1001, Kessl et al.,
2012; CHIBA3053, De Luca et al., 2009; CX05045, Christ et al., 2010; CX14442, Christ et al., 2012). (B) Cartoon representation of the co-crystal structure of compound 6
(yellow stick superimposed with the IBD–IN core complex structure, gray) bound in the LEDGF/p75 binding pocket of HIV-IN (green and yellow) (PDB 3LPU) reveals
mimicry of the protein–protein interaction by compound 6 (Christ et al., 2010).
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dimerization of HIV-IN, an effect consistently observed for other
potent LEDGINs (see below), pointing toward a divergent
mechanism of action. Although D77 failed to inhibit LEDGF/
p75–IN interaction in Alphascreen based assays, it inhibited the
LEDGF/p75–IN interaction in a yeast two-hybrid based cellular
reporter assay. Minor antiviral activity in MT-4 cells was
described, but the activity versus toxicity (selectivity index¼SI)
window reported was rather narrow.
Recently the same group reported a new structure based
approach to identify inhibitors of the LEDGF/p75–IN interaction
(Hu et al., 2012). In this study 26 known drugs were selected
based on the GlideSP program allowing for ﬂexible docking of the
ligands (Friesner et al., 2004). Of the initially selected drugs eight
were indeed capable of inhibiting the LEDGF/p75–IN interaction
with moderate IC50 values ranging from 6.54 mM for Carbidopa to
36.85 mM for Eprosartan. Of note one of the selected compounds,
Atorvastatin (IC50 8.9 mM), has been used in HIV patients to
reduce cholesterol levels and an effect on HIV-replication has
been reported. Whether the in vitro and antiviral activities indeed
are linked with each other is still hypothetical though and
requires further investigation.
On the basis of a pharmacophore model, comprised of 14
distinct features derived from the IBD–IN–CCD co-crystal struc-
ture and including potential steric restrictions, a virtual screening
approach was performed (De Luca et al., 2010). The contacts of
LEDGF–Ile365 with IN–Gln168 and Asp366 with IN–Glu170/171
formed the basis of the model. Best ﬁtting was obtained for
CHIBA-3002, a small molecule which was previously described as
an IN strand transfer inhibitor, suggesting a dual function of this
small molecule. Indeed modest inhibition of the LEDGF/p75–IN
interaction was observed in the Alphascreen assay. Docking of
more potent congeners of these benzylindole derivatives high-
lighted that the CHIBA compounds likely form hydrogen bonds
with the main chains of IN–Glu170 and His171 while the diketo
acid moiety creates a hydrogen bond with Gln95 of the other IN–
CCD subunit. Follow-up studies explored the chemical space
further toward the LEDGF–Phe406 contact with Trp131 and
generated a more potent congener of the compounds, CHIBA-
3053 (Fig. 3A), with an IC50 in the lower micromolar range.Further optimization though is needed to reach antiviral activity
for this class of small molecules. Recent molecular docking
studies by De Luca et al. (2011) suggest that inhibitors previously
identiﬁed as INSTIs (CHI-1043), which are based on the classical
diketoacid functionality, might serve as LEDGF/p75–IN inhibitors.
Indeed they observed that CHI-1043 which potently inhibits HIV-
replication (De Luca et al., 2008) is a weak inhibitor of the LEDGF/
p75–IN interaction. Whether this weak SMPPII mechanism con-
tributes to the antiviral activity is uncertain and inhibitors with
more equal activities on both functionalities would be necessary
to dissect the detailed mechanism of action.
Fan et al., 2011 used a scaffold hopping approach to design yet
another set of small molecules capable of inhibiting the catalytic
site as well as the LEDGF/p75–IN interaction. As a starting point
the pharmacophores of salicylic acid and catechol were fused and
therefore a molecule was generated capable of chelating the
catalytic Mg2þ ions in the active site and of binding into the
hydrophobic pocket formed by the dimer interface in the IN–CCD.
Four different classes of compounds were described with the
most potent compound (compound 5u) reaching moderate activ-
ity for the inhibition of the 30 processing and strand transfer
reaction of IN (IC50 53 mM and 19 mM). The compound did not
induce any cytotoxicity in H630 cells, but no antiviral activity was
reported either. Further optimization of the described structures
is required to reach higher activities in vitro as well as antiviral
activity. Whether the strategy of designing compounds that bind
both the catalytic site of integrase but also the hydrophobic
LEDGF/p75 interaction site and therefore inhibit both functional-
ities of HIV-IN simultaneously, will be a valid strategy to potently
inhibit integration with a reduced risk of resistance selection, or
will lead to undesired side effects due to unequal afﬁnity for both
inhibitory sites remains to be investigated.
The so far described efforts of LEDGIN development started
from molecular modeling approaches based on the co-crystal
structure of LEDGF/p75 IBD and HIV-IN. As described above an
intensive crystallization effort had been undertaken to identify
yet unknown contacts between small cyclic LEDGF/p75 derived
peptides with the catalytic core domain of integrase (Rhodes
et al., 2011). In this effort a hydrogen bonding interaction with
IN–Gln168 was identiﬁed not exploited in any of the other
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study using fragment based screening to identify small molecules
making use of this contact which eventually might lead to the
development compounds with a higher afﬁnity and/or a higher
barrier to resistance (Peat et al., 2012). Initially 500 fragments
were screened using SPR, NMR and crystallography identifying
hits with good density in the LEDGF/p75 binding site of integrase.
Synthesis of small molecules based on the hits of the initial
fragment based screening led to compound 11 with an IC50 at
8.1 mM in the Alphascreen based LEDGF/p75-IN interaction assay.
Crystallography indeed demonstrated that compound 11 pene-
trates deep into the hydrophobic pocket on the IN-dimer interface
directly interacting with IN–Gln168 and therefore indeed target-
ing the 167–173 interaction site for LEDGF/p75 in IN. Compound
11 has moderate antiviral activity with an EC50 of 29 mM and no
apparent toxicity and is not cross-resistant with raltegravir
resistance mutants such as IN Q148H/G140S and N155H/E92Q.
Future resistance selection and cross-resistance testing with
known LEDGINs resistant mutants will demonstrate whether
expansion deeper into the dimer interface will raise the barrier
toward resistance selection for this class of LEDGINs.2-(tert-butoxy)-2-substituted acetic acid derivatives, LEDGINs
with antiviral activities in the nanomolar range
In 2010 we reported the structure-based design of CX04238
and CX05045 both belonging to the class of 2-(tert-butoxy)-2-
substituted acetic acid derivatives (Christ et al., 2010; Fig. 3). This
work was founded by the construction of a consensus pharma-
cophore based on different available crystal structures of the CCD
of HIV-IN (Cherepanov et al., 2005a; Maignan et al., 1998; Molteni
et al., 2001), representing a series of steric and electronic features
predicted to be critical for LEDGF/p75 binding in the hydrophobic
pocket at the IN dimer interface. Around 200,000 commercially
available diverse compounds were ﬁltered, ﬁtted to the pharma-
cophore model and best scoring hits were cherry picked and
subjected to biological evaluation. Four compounds weakly
inhibited the LEDGF/p75–IN interaction and constituted the basis
for a detailed structure–activity relationship (SAR) investigation
aiming at developing more potent analogs with beneﬁcial med-
icinal chemistry characteristics. Co-crystals of the identiﬁed hit
compounds with the IN–CCD were obtained and conﬁrmed the
initial pharmacophore. The LEDGIN phenyl, acid and chlorine
groups were indeed mimicking LEDGF/p75 Ile365, Asp366 and
Leu368. This structural information was crucial to design and
synthesize more potent LEDGINs with improved biological activ-
ities, such as CX05045 (Christ et al., 2010) and CX014442 (Christ
et al., 2012; Fig. 3A), allowing for a complete antiviral proﬁling of
this compound class. CX014442 is the ﬁrst LEDGIN reported to
display antiviral activity in the low nanomolar range, EC50
IIIB¼6973 nM and high selectivity, SI¼1391. To date the 2-
(tert-butoxy)-2-substituted acetic acid derivatives are the best
studied LEDGINs and congeners of these compounds are in
advanced preclinical development.
Unlike strand transfer inhibitors, LEDGINs inhibit the strand
transfer and 30 processing reactions to the same extent. Complete
inhibition of the integrase catalytic activities by LEDGINs can only
be achieved when the compounds are added to integrase before
the DNA substrate (Christ et al., 2012; Kessl et al., 2012; Tsiang
et al., 2012). This is in stark contrast with the uncompetitive
mode of inhibition of INSTIs that require prior binding and 30
processing of viral DNA ends (Espeseth et al., 2000; Hare et al.,
2010). The inhibition of both catalytic activities of integrase
suggests that LEDGIN binding inﬂuences the active site of inte-
grase. Indeed we and others provided evidence that LEDGINsmodulate the multimeric state of integrase upon their binding
(Christ et al., 2012; Kessl et al., 2012; Tsiang et al., 2012). LEDGIN
binding to the integrase dimer interface leads to a stabilization of
the dimer, restricting integrase oligomeric ﬂexibility and as a
consequence affecting the productive formation of the intasome.
LEDGF/p75 in turn likely modulates the integrase multimeriza-
tion required for enzymatic activity (Kessl et al., 2011). Hence
LEDGF/p75 can be considered an allosteric effector of integrase
activity and LEDGINs as allosteric enzymatic inhibitors. Thus next
to their SMPPII function LEDGINs are genuine allosteric inhibitors
(Christ et al., 2012; Kessl et al., 2012; Tsiang et al., 2012). Tsiang
et al. (2012) demonstrated that in cell culture LEDGINs induce a
signiﬁcant decrease of deletions at the 2-LTR junctions in 2-LTR
circles produced during HIV-replication consistent with an anti-
viral mechanism involving the inhibition of 30 processing and thus
consistent with the observations of the biochemical characteriza-
tions. Both, the PPI and allosteric mechanisms are relevant for
their biological activity, cannot be uncoupled and lead to the
inhibition of the integration reaction. In the discussion whether
one mechanism should be considered more important than the
other, one should keep in mind that in vivo LEDGINs will always
encounter LEDGF/p75 bound to the dimer interface of integrase
and therefore are required to displace LEDGF/p75 which is
essential for HIV replication (Schrijvers et al., 2012).
Alike INSTIs, LEDGINs inhibit the integration step of HIV-
replication as shown by quantitative PCR (Q-PCR) and Time-of-
addition (TOA) studies (Christ et al., 2012, 2010). Importantly
though LEDGINs are by no means cross-resistant with INSTIs.
Initial resistance selection with less potent LEDGINs demon-
strated that a single point mutation is sufﬁcient to render HIV
resistant to the action of LEDGINs (Christ et al., 2010). Integrase
Ala128 makes substantial Van der Waals contacts with LEDGF/
p75–Ile365 and Leu368, both important features in the pharma-
cophore model. Hence the ﬁnding that an Ala128 to Threonin
substitution reduced LEDGIN binding to integrase did not come at
a surprise. The more recent report that more potent LEDGINs
though are active against A128T and that at least one additional
resistance mutation is required to render integrase resistant
against LEDGIN action (Christ et al., 2012) proves that the
expansion of the chemical space raises the barrier towards
resistance development, an observation, which will be important
for further clinical development of this compound class. Impor-
tantly LEDGINs retain their activity in primary cells and are active
against a broad spectrum of clades and clinical isolates (Christ
et al., 2012, 2010). Combination experiments demonstrate that
LEDGINs and INSTIs do not antagonize each other but act in an
additive or even slightly synergistic way, implementing a possible
design of LEDGIN/INSTI combination therapy within the HAART
treatment schemes (Christ et al., 2012).
The detailed virological characterization of cyclic peptides
(CPs) binding to LEDGF/p75 and therefore inhibiting HIV-
replication when expressed in cell culture, provided the ﬁrst
evidence that inhibition of the LEDGF/p75–IN interaction results
in impaired infectivity of viral particles produced in presence of
this peptide inhibitor (Desimmie et al., 2012). The most recent
report on the mechanism of action of LEDGINs conﬁrms this
multimodal inhibition pathway (Christ et al., 2012). Presence of
LEDGINs during virus production indeed not only blocks provirus
integration but affects as well the infectivity of the residual
progeny virus. This observation is unique for LEDGINs and is not
part of the mechanism of other integration inhibitors such as
raltegravir or other classes of early replication inhibitors, such as
entry blockers, NRTIs (nucleoside reverse transcriptase inhibitors)
or NNRTIs (non-nucleoside reverse transcriptase inhibitors). The
ﬁnding that LEDGINs not only block the integration of the viral
genome but additionally impair the infectivity of viral particles,
F. Christ, Z. Debyser / Virology 435 (2013) 102–109108when present during production, makes them highly interesting
candidates further clinical development.Conclusions
In the past decade the identiﬁcation, validation and targeting of
LEDGF/p75 for antiviral therapy represents one of most thrilling
research lines in the ﬁeld of HIV virology. Intensive medicinal
chemistry efforts by multiple groups have proven the feasibility of
targeting the LEDGF/p75–IN interaction for anti-HIV drug devel-
opment and as such might also pave the way for exploiting other
virus-host interaction involved in integration, but also in other
steps of the viral replication cycle, for drug discovery.
While the development of LEDGINs has experienced a promis-
ing start, a long winding road still needs to be taken to reach the
clinic in the future. The fate of this novel class of inhibitors will
not be solely depending on the antiviral activity but more
importantly on pharmacokinetics and tolerability. However their
multimodal mode of action is unique in the ﬁeld of HIV-drug
discovery holding great promise for the treatment of HIV/AIDS.
The divergent resistance pathway of LEDGINs in comparison with
INSTI and the lack of cross-resistance with any known class of
ARVs make them candidates for future HAART, especially for
patients failing on current therapy. More importantly the severe
hampering of infectivity of viruses produced in presence of
LEDGINs raises particularly the interest for further development.
Although ﬁnal proof will only be given when LEDGINs are an
integral part of antiviral therapy, it is easy to imagine that the
combined early (integration) and late effect (infectivity) not only
increases the steepness of the slope in the inhibition of HIV-
replication but will ultimately raise the barrier of resistance
development in patients. Combined early and late effects deﬁne
LEDGINs as unique within all classes of HIV-drugs described so far
and might predestinate them for use in prevention and ﬁrst in
line therapy.Acknowledgments
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